| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | RXRX | Class A Common Stock | Purchase | $754,421 | +100,378 | +0.89% | $7.52 | 11,392,315 | 23 Dec 2022 | See Explanation of Responses | F1, F2, F13, F15, F16 |
| transaction | RXRX | Class A Common Stock | Purchase | $1,054,404 | +145,652 | +1.3% | $7.24 | 11,537,967 | 27 Dec 2022 | See Explanation of Responses | F1, F3, F13, F15, F16 |
| transaction | RXRX | Class A Common Stock | Purchase | $511,898 | +71,299 | +0.62% | $7.18 | 11,609,266 | 28 Dec 2022 | See Explanation of Responses | F1, F4, F13, F15, F16 |
| transaction | RXRX | Class A Common Stock | Purchase | $652,774 | +84,622 | +0.73% | $7.71 | 11,693,888 | 29 Dec 2022 | See Explanation of Responses | F1, F5, F13, F15, F16 |
| transaction | RXRX | Class A Common Stock | Purchase | $753,622 | +99,754 | +0.85% | $7.55 | 11,793,642 | 30 Dec 2022 | See Explanation of Responses | F1, F6, F13, F15, F16 |
| transaction | RXRX | Class A Common Stock | Purchase | $1,063,011 | +141,646 | +1.2% | $7.50 | 11,935,288 | 03 Jan 2023 | See Explanation of Responses | F1, F7, F13, F15, F16 |
| transaction | RXRX | Class A Common Stock | Purchase | $716,877 | +91,892 | +0.77% | $7.80 | 12,027,180 | 04 Jan 2023 | See Explanation of Responses | F1, F8, F13, F15, F16 |
| transaction | RXRX | Class A Common Stock | Purchase | $590,554 | +80,035 | +0.67% | $7.38 | 12,107,215 | 05 Jan 2023 | See Explanation of Responses | F1, F9, F13, F15, F16 |
| transaction | RXRX | Class A Common Stock | Purchase | $510,611 | +68,953 | +0.57% | $7.41 | 12,176,168 | 06 Jan 2023 | See Explanation of Responses | F1, F10, F13, F15, F16 |
| transaction | RXRX | Class A Common Stock | Purchase | $580,839 | +76,046 | +0.62% | $7.64 | 12,252,214 | 09 Jan 2023 | See Explanation of Responses | F1, F11, F13, F15, F16 |
| transaction | RXRX | Class A Common Stock | Purchase | $536,846 | +69,518 | +0.57% | $7.72 | 12,321,732 | 10 Jan 2023 | See Explanation of Responses | F1, F12, F13, F15, F16 |
| holding | RXRX | Class A Common Stock | 7,062,869 | 23 Dec 2022 | See Explanation of Responses | F14, F15, F16 |
| Id | Content |
|---|---|
| F1 | This is an inadvertent late filing due to an administrative error. |
| F2 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.38 to $7.70, inclusive. The reporting person undertakes to provide to Recursion Pharmaceuticals, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (12) to this Form4. |
| F3 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.12 to $7.61, inclusive. |
| F4 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.07 to $7.32, inclusive. |
| F5 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.25 to $7.91, inclusive. |
| F6 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.33 to $7.72, inclusive. |
| F7 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.37 to $7.83, inclusive. |
| F8 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.52 to $7.88, inclusive. |
| F9 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.30 to $7.75, inclusive. |
| F10 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.10 to $8.00, inclusive. |
| F11 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.43 to $8.00, inclusive. |
| F12 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.52 to $8.00, inclusive. |
| F13 | Consists of 12,321,732 shares held of record by Fifteenth Investment Company LLC. Fifteenth Investment Company LLC is wholly owned subsidiary of Mamoura Diversified Global Holdings PJSC, which is wholly owned by Mubadala Investment Company PJSC, which is wholly owned by the Government of Abu Dhabi. |
| F14 | MDC Capital Partners (Ventures) GP, LP is the general partner of MDC Capital Partners (Ventures), LP, which directly holds 7,062,869 shares of Class A Common Stock ("Class A Shares"). MDC Capital Partners (Ventures) GP, LP has created an investment committee comprised of four individual members, which has the authority, by affirmative majority consent, to approve all investment and divestment decisions made with respect to MDC Capital Partners (Ventures), LP. Each of the members of the investment committee expressly disclaims beneficial ownership of the shares held by MDC Capital Partners (Ventures), LP. |
| F15 | Because of the relationship among the Reporting Persons, the Reporting Persons may be deemed to own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any. |
| F16 | Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. |
17. The Reporting Persons are jointly filing this Form 4 pursuant to Rule 16a-3(j) under the Exchange Act.